Conditions: Focal Epilepsy
Keywords: epilepsy antiepileptic biotherapy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 111
Healthy volunteers: no

Brief summary:
Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide
Intervention descriptions: intervention 1: * Gabapentin: up to 3.600 mg/d
* Lamotrigine: up to 400 mg/d
* Levetiracetam: up to 3.000 mg/d
* Pregabalin: up to 600 mg/d
* Oxcarbazepine: up to 2.400 mg/d
* Tiagabine: up to 30 mg/d
* Topiramate: up to 400 mg/d
* Zonisamide: up to 500 mg/d

Protocol document: